MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

2025 — Scientists have developed an innovative solar-powered method to transform sewage sludge -- a by-product of wastewater treatment -- into green hydrogen for clean energy and single-cell ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, harnessing the power of living cells to transform lives. We know that every research ...

An in vivo single-cell electroporation method enables the delivery of plasmids selectively to individual pyramidal neurons in the mouse dorsal hippocampus, guided by two-photon imaging.

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...

In a new deal, TG Therapeutics will use MaxCyte’s engineering technology to develop and manufacture its off-the-shelf CAR T-cell therapy ... to MaxCyte’s flow electroporation technology ...